AbbVie pays Frontier $55M to pursue hard-to-drug targets

[cafead]

via AbbVie has teamed up with Frontier Medicines to develop molecules against hard-to-drug targets. The collaborators will use Frontier’s technology for uncovering hidden binding pockets to develop protein degraders and small molecules against oncology and immunology targets.

article source